Clinical trials: Infarction, Brain
Acute Stroke
Cytoflavin in Combination With Reperfusion in Stroke Patients
Evaluation of the efficacy and safety of Cytoflavin®, solution for intravenous administration, (OOO NTFF POLYSAN, Russia) for 10 days, patients with cerebral infarction who receive reperfusion therapy, with the start of treatment…
- Trial name
- NCT05297851
- Testing
- Cytoflavin (succinic acid + inosine + nicotinamide + riboflavin), Control
- Where
- 7 sites in Russia
- Volunteers
- 200 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Acute Ischemic Stroke, Transient Ischemic Attack (TIA)
A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
The purpose of this clinical study is to determine whether the addition of an oral Factor XIa Inhibitor to Aspirin and Clopidogrel is more effective than standard therapy in secondary stroke prevention.
- Trial name
- AXIOMATIC-SSP (NCT03766581)
- Testing
- BMS-986177, Clopidogrel, Aspirin
- Where
- 424 sites in United States, Argentina and 27 more
- Volunteers
- 2,366 people
- Sponsor
- Bristol-Myers Squibb
Thrombosis, Acute Coronary Syndrome
Safety, Pharmacokinetic and -Dynamic Study of PR-15, an Inhibitor of Platelet Adhesion
Primary objective: To evaluate safety and tolerability, adverse events (AEs), vital signs, ECG, bleeding time, evaluation of antibody titer and safety laboratory tests Secondary objectives: To evaluate the pharmacokinetics and…
- Conditions
- Thrombosis, Acute Coronary Syndrome, Myocardial Infarction, Stroke
- Trial name
- PR-15/01 (NCT01042964)
- Testing
- revacept (PR-15)
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AdvanceCor GmbH
Heart Failure, Coronary Artery Disease
A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
The purpose of this study is to assess the effectiveness and safety of rivaroxaban compared with placebo (inactive medication), in reducing the risk of death, myocardial infarction or stroke in participants with heart failure and…
- Trial name
- COMMANDER HF (NCT01877915)
- Testing
- Rivaroxaban, Standard of care for heart failure and coronary artery disease
- Where
- 562 sites in United States, Argentina and 30 more
- Volunteers
- 5,081 people
- Sponsor
- Janssen Research & Development, LLC
Transcranial Bone Marrow Injection, RK-4
RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction
An open-label, blinded Ib/IIa study investigating the treatment of acute large hemispheric infarction by transcranial bone marrow injection of RK-4 injection For subjects with acute large hemispheric infarction who are…
- Conditions
- Transcranial Bone Marrow Injection, RK-4, Acute Large Hemispheric Infarction, Acute Ischemic Stroke
- Trial name
- NCT07166380
- Testing
- RK-4 injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Neurodawn Pharmaceutical Co., Ltd.
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function.
- Trial name
- NCT06383390
- Testing
- Retatrutide
- Where
- 742 sites in United States, Argentina and 25 more
- Volunteers
- 10,000 people
- Sponsor
- Eli Lilly and Company
Cerebral Infarction
Efficacy and Safety Study of Cilostazol to Prevent Reoccurrence of Stroke
The study design is subject to relevant SFDA regulations about clinical trials. This indication was approved in Japan in 2003. From the end of May 2004 to the end of Dec.
- Trial name
- NCT00202020
- Testing
- Cilostazol 200mg/day Oral, Aspirin 100mg/day Oral
- Where
- 12 sites in China
- Volunteers
- 720 people
- Sponsor
- Otsuka Beijing Research Institute
Diabetes Mellitus, Type 2, Acute Coronary Syndrome
Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome
The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in patients with type 2 diabetes mellitus and acute coronary syndrome.
- Trial name
- EXAMINE (NCT00968708)
- Testing
- Alogliptin
- Where
- 908 sites in United States, Argentina and 48 more
- Volunteers
- 5,380 people
- Sponsor
- Takeda
Prevention & Control
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
The primary objectives of this study are: To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction…
- Trial name
- COMPASS (NCT01776424)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Pantoprazole
- Where
- 565 sites in United States, Argentina and 31 more
- Volunteers
- 27,395 people
- Sponsor
- Bayer
Cerebral Infarction
Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Dose-responsive Clinical Pharmacology Study
Sarpogrelate is an antiplatelet agent that decreases 5-hydroxytryptamine( 5-HT )levels in platelets via blockade of 5-HT2 receptors, has been used in atherosclerotic peripheral arterial disease.
- Trial name
- NCT00147303
- Testing
- MCI-9042
- Volunteers
- 46 people
- Sponsor
- Tanabe Pharma Corporation
Dysphagia Following Cerebral Infarction
Pharyngeal Electrical Stimulation Evaluation for Dysphagia After Stroke
This is a randomized, sham-controlled, patient masked, outcome assessor-blinded study to assess a Pharyngeal Electrical Stimulation (PES) Catheter for treatment of oropharyngeal dysphagia following a stroke.
- Trial name
- PhEED (NCT03358810)
- Testing
- PES
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Phagenesis Ltd.
Quadriplegia, Amputations
A Study on the Safety and Functionality of the Implantable Wireless Brain-Computer Interfaces for Motor Rehabilitation
The objective of this study is to evaluate the safety and efficacy of minimally invasive, wireless brain-machine interface system (WRS) in patients with paralysis (resulting from spinal cord injuries, brainstem strokes…
- Conditions
- Quadriplegia, Amputations, Spinal Cord Injuries (SCI), Brainstem Stroke
- Trial name
- STAIR (NCT06944834)
- Testing
- Implant
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Shanghai StairMed Technology Co., Ltd.
Atherosclerosis Cerebral Infarction
Study of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject
Randomized, control, open label, multicentre clinical study. The patient who are in accordance with subject inclusion and exclusion criteria will be randomized to A group: Routine treatment B group: Routine treatment+ Cilostazol…
- Trial name
- NCT00823875
- Testing
- Cilostazol group, Probucol group, Cilostazol + Probucol group
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Otsuka Beijing Research Institute
Cerebral Infarction
Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)
The study is designed to assess safety of Vorapaxar when added to standard of care (aspirin) in Japanese subjects with cerebral infarction.
- Trial name
- NCT00684515
- Testing
- Vorapaxar 2.5 mg, Vorapaxar 1 mg, Aspirin 75-150 mg
- Volunteers
- 90 people
- Sponsor
- Merck Sharp & Dohme LLC
Cardiovascular Disease, Myocardial Infarction
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial…
- Conditions
- Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
- Trial name
- EVOLVE-MI (NCT05284747)
- Testing
- Evolocumab, Routine Lipid Management
- Where
- 120 sites in United States, Brazil and 1 more
- Volunteers
- 6,019 people
- Sponsor
- Amgen
Stroke, Ischemic Stroke
Gravity Stroke System for Recanalization of Large Vessel Occlusion Strokes
Supernova and Neutron are endovascular mechanical revascularization devices indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing an acute ischemic stroke within 24 hours…
- Conditions
- Stroke, Ischemic Stroke, Cerebrovascular Disorders, Brain Diseases
- Trial name
- GRASSROOT Reg (NCT07335185)
- Testing
- Supernova revascularization device
- Volunteers
- 3,000 people
- Sponsor
- Gravity Medical Technology, INC
Stroke, Stroke, Acute
Volumetric Integral Phase-shift Spectroscopy for Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology
The purpose of this study is to assess the ability of the Fluids Monitor to detect hemispheric bioimpedance asymmetry associated with acute brain pathology in patients presenting with suspected Acute Ischemic Stroke (AIS).
- Conditions
- Stroke, Stroke, Acute, Ischemic Stroke, Hemorrhage
- Trial name
- VITAL (NCT03148340)
- Testing
- VIPS Monitoring
- Where
- 5 sites in United States
- Volunteers
- 287 people
- Sponsor
- Cerebrotech Medical Systems, Inc.
Cerebral Infarction
Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)
Sarpogrelate (MCI-9042) is an antiplatelet drug that decreases 5-hydroxytryptamine (5-HT) levels in platelets via a blockade of 5-HT2 receptors; it has been used in atherosclerotic peripheral arterial disease.
- Trial name
- NCT00129805
- Testing
- MCI-9042, Aspirin
- Volunteers
- 1,510 people
- Sponsor
- Tanabe Pharma Corporation
Cerebral Stroke
Hyperbaric Oxygen Therapy After Stroke - PILOT
The goal of this pilot study is to establish more information about hyperbaric oxygen therapy for this group of patients, and give us more information of how to initiate the best possible main study.
- Trial name
- NCT04149379
- Testing
- Hyperbaric oxygen
- Where
- Norway
- Sponsor
- Norwegian Underwater Intervention (NUI)
Stroke
OASIS STUDY Outcome Assessment Using SF-36 v2 in Stroke Patient Study(OASIS STUDY)
1. To survey the health-related quality of life using the SF-36v2 score of patients with chronic brain infarction in Japan 2. Chronic brain infarction in Japan is better than EU/USA
- Trial name
- NCT00281034
- Where
- Japan
- Volunteers
- 2,069 people
- Sponsor
- Kyorin Pharmaceutical Co.,Ltd